Table 2.
Temporal trends in invasive breast cancer among women in the National Cancer Institute's SEER 9 Registries database for three time periods: 1975 through 1979, 1990 through 1994, and 2000 through 2004*
| 1975–1979 (n = 48 285) |
1990–1994 (n = 79 642) |
2000–2004 (n = 94 446) |
|||||
| Variable | No. | Rate (95% CI) | No. | Rate (95% CI) | No. | Rate (95% CI) | %CH (95% CI) |
| Age, y (1975+) | |||||||
| <40 | 3263 | 12.6 (12.1 to 13.0) | 5099 | 13.0 (12.6 to 13.3) | 5109 | 13.3 (12.9 to 13.7) | 5.8 (5.6 to 6.0) |
| 40–49 | 7792 | 138.3 (135.3 to 141.5) | 13 429 | 159.4 (156.4 to 162.1) | 16 602 | 152.7 (150.4 to 155.1) | 10.4 (10.1 to 10.7) |
| 50–69 | 23 344 | 233.0 (230.0 to 236.0) | 33 098 | 308.2 (304.9 to 311.6) | 42 239 | 321.7 (318.7 to 324.8) | 38.1 (35.3 to 41.1) |
| ≥70 | 13 886 | 333.8 (339.4 to 462.7) | 28 016 | 462.7 (457.3 to 468.2) | 30 496 | 441.0 (436.1 to 446.1) | 32.1 (29.1 to 35.5) |
| Race (1975+) | |||||||
| White | 43 592 | 104.8 (103.8 to 105.8) | 68 838 | 135.8 (134.8 to 136.8) | 78 566 | 136.5 (135.5 to 137.4) | 30.2 (29.3 to 31.1) |
| Black | 3123 | 87.8 (84.6 to 91.1) | 6357 | 120.0 (117.0 to 123.1) | 8349 | 117.8 (115.3 to 120.4) | 34.2 (30.3 to 38.5) |
| Other or unknown | 1570 | — | 4447 | — | 7531 | — | — |
| Tumor size (1988+) | |||||||
| <2.0 cm | — | — | 43 498 | 71.8 (71.1 to 72.4) | 55 342 | 77.1 (76.5 to 77.8) | 7.5 (7.4 to 7.5) |
| ≥2.0 cm | — | — | 24 580 | 40.6 (40.1 to 41.1) | 29 508 | 40.8 (40.3 to 41.2) | 0.5 (0.5 to 0.5) |
| Other or unknown | — | — | 11 564 | — | 9596 | — | — |
| Lymph node status (1988+) | |||||||
| Negative | — | — | 41 927 | 69.6 (68.9 to 70.2) | 51 719 | 72.5 (71.8 to 73.1) | 4.2 (4.2 to 4.3) |
| Positive | — | — | 21 115 | 35.3 (34.8 to 35.8) | 27 339 | 38.2 (37.8 to 38.7) | 8.2 (8.1 to 8.3) |
| Other or unknown | — | — | 16 600 | — | 15 388 | — | — |
| Tumor grade (1975+) | |||||||
| Low | 3013 | 6.4 (6.2 to 6.6) | 27 723 | 45.7 (45.2 to 46.2) | 53 817 | 74.7 (74.1 to 75.3) | 1066.6 (400.3 to 2842.0) |
| High | 5471 | 11.5 (11.8 to 38.0) | 22 818 | 38.0 (37.5 to 38.5) | 31 184 | 43.5 (43.0 to 44.0) | 277.4 (214.6 to 358.5) |
| Other or unknown | 39 801 | — | 29 101 | — | 9445 | — | — |
| ER status (1990+) | |||||||
| Positive | — | — | 45 254 | 74.4 (73.7 to 75.1) | 64 126 | 89.1 (88.4 to 89.8) | 19.7 (19.3 to 20.0) |
| Negative | — | — | 14 604 | 24.6 (24.2 to 25.0) | 17 516 | 24.5 (24.1 to 24.9) | −0.5 (−0.5 to −0.6) |
| Other or unknown | — | — | 19 784 | — | 12 804 | — | — |
Data for rate are the number of patients per 100 000 woman-years (age adjusted to the US standard population for the year 2000). Year in parenthesis indicates the time period in which SEER collected data for a given tumor characteristic. For example, SEER recorded age at diagnosis from 1975 forward (1975+). Because SEER did not collect and/or record all tumor characteristics for all time periods, rates and percent change are calculated only for those patients with breast cancer who had available data. Rate = the number of patients diagnosed with breast cancer per 100 000 woman-years (age adjusted to the US standard population for the year 2000); SEER = Surveillance, Epidemiology, and End Results; CI = confidence interval; %CH = percent change from 1975–1979 or 1990–1994 to 2000–2004; ER = estrogen receptor; — = not calculated and/or data not available.